Summary Characterisation of altered glycosylation of P-glycoprotein (P-gp) found associated with the absence of a multidrug resistance (MDR) phenotype in cell lines prompted an investigation to assess the role of post-translational processing in establishing P-gp efflux pump functionality. The clone A cell line used in this study displays a strong MDR phenotype mediated by high constitutive levels of expression of P-gp. Incubation of clone A cells with tunicamycin for different periods resulted in a time-dependent increase in daunorubicin accumulation, reflecting a reduction in P-gp function. Parallel experiments conducted with verapamil resulted in no loss of P-gp functionality in clone A cells. Reduction in surface-associated P-gp following exposure to tunicamycin was established by FACS analysis, Western blot analysis and immunoprecipitation of surface-iodinated P-gp. In addition, immunoprecipitation of P-gp from 32p_ orthophosphate-labelled cells demonstrated reduced phosphorylation of P-gp associated with tunicamycin exposure. From these studies we conclude that glycosylation of P-gp is required to establish the cellular MDR phenotype.
Various steps in the biosynthesis of P-glycoprotein (P-gp) were characterised in a number of previous studies and demonstrated that P-gp is synthesised as a 140kDa precursor, processed via N-linked glycosylation to a mature 170kDa transmembrane glycoprotein (Greenberger et al., 1988; Richert et al., 1988; Loo and Clarke, 1994) . A second step in the biosynthesis involves phosphorylation of the mature 170kDa glycoprotein (Richert et al., 1988) , which is considered to be an essential event in establishing a fully functional efflux pump (Hamada et al., 1987; Bates et al., 1992; Kramer et al., 1993a,b) . Since the 140 kDa precursor molecule is not phosphorylated in the resting state (Kramer et al., 1993a) and the mature 170 kDa protein is localised in the membrane, it is likely that phosphorylation is mediated by kinases acting at the plasma membrane (Staats et al., 1990) . Modulation of the phosphorylation and functional status of P-gp by the tumour promoter phorbol ester 4p-phorbol 12p myristate 13az-acetate suggests that protein kinase C (PKC) may be one kinase mediating this event (Hamada et al., 1987; Chambers et al., 1990 Chambers et al., , 1992 . In addition, P-gp has been shown to be an in vitro substrate for protein kinase A (PKA) (Mellado and Horowitz, 1987) , and both PKC and PKA phosphorylation domains have been identified (Orr et al., 1993) . Although the phosphorylation status of P-gp has been shown to be strongly correlated with the MDR phenotype in cell lines (Kramer et al., 1993a) , there is little direct evidence demonstrating a requirement for phosphorylation in establishing functionality. However, a recent study by Bates et al. (1992) has demonstrated an association between decreased P-gp phosphorylation and increased drug accumulation in a human colon cell line exposed to sodium butyrate. Moreover, antisense DNA directed against PKC3 a has been shown to decrease the drug resistance of MCF-7/Adr cells (Ahmed and Glazer, 1993) .
In contrast, glycosylation events associated with maturation of the 140 kDa precursor molecule are not considered important in establishing the functionality of the P-gp efflux pump (Chou and Kessel, 1981; Beck and Cirtain, 1982) . Two lines of evidence suggest this to be the case. First, exposure of a drug-resistant cell line, CEM/VLB100, to pronase or tunicamycin does not diminish the activity of drug efflux in these cells (Beck and Cirtain, 1982) . Second, colchicineresistant hamster cell mutants displaying an altered carbohydrate moiety of P-gp retain a competent MDR phenotype in drug uptake assays (Ling et al., 1983) . Our previous studies, using a panel of human colon carcinoma cell lines, have identified two P-gp mutants in which altered processing of similar levels of the immature P-gp results in markedly different MDR phenotypes (Kramer et al., 1993a 1993a). Tunicamycin was added to complete medium at a final concentration of 2.5p,gmlm' (3pM). Verapamil was used at a final concentration of 4 gmlml (10pM).
Immunoprecipitation of P-gp and epidermal growth factor receptor (EGFR) Subconfluent dishes of cell lines were washed twice in phosphate-buffered saline (PBS) and incubated for 1 h in methionine-free or phosphate-free DMEM followed by incubation in [35S]methionine (150 l.Ci ml-') or [32P]orthophosphate (150ftCiml-') respectively. In pulse chase experiments cells were labelled for 10 min and chased in complete DMEM for different periods. In all other experiments labelling was for 3 h followed by immunoprecipitation of P-gp using the same protocol. Metabolically labelled cells were rinsed briefly in phosphate-buffered saline (PBS) and lysed in PBSTDS buffer (PBS pH 7.4, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 2mM phenylmethylsulphonylfluoride, 10 U ml-' aprotinin). Lysis was carried out for 20 min at 4°C, followed by shearing of lysates through a 24 gauge needle. Lysates were clarified in a microfuge for 20 min at 4°C, supernatants were removed and 10 jl aliquots were taken for protein estimation using the bovine serum albumin (BSA) protein assay system (Pierce, Rockford, IL, USA). Before immunoprecipitation samples were standardised for protein concentration. Overnight incubation of lysates at 4°C with MDR-1 polyclonal antibody (Oncogene Science, Uniondale, NY, USA) was followed by a 90 min incubation with protein A-Sepharose beads. Immune complexes were washed three times in PBS then incubated in standard sample buffer for 20 min at room temperature. All samples were run on 7.5% polyacrylamide gels, dried and exposed for 1-3 days on X-ray film.
Functional assays P-gp activity was determined using a daunorubicin accumulation assay (Kramer et al., 1993a) . Replicate suspensions of colon cells (2 x 106 cells ml-') were incubated at 37°C for 90 min in medium containing daunorubicin (3 tiM) in the presence or absence of verapamil or tunicamycin. In a separate experiment, cells were exposed to tunicamycin (2.5 lg ml-') or verapamil (4 Itg ml-') for 24-36 h, washed twice in PBS and then assayed for daunorubicin accumulation, as described above. Cellular daunorubicin fluorescence was quantitated by flow cytometric analysis using BectonDickinson (Mountain View, CA, USA) FACSort and LYSYS II software.
Flow cytometry
Surface staining of cells for P-gp expression was accomplished using the 4E3 anti-Pg-p monoclonal antibody (MAb) (Arceci et al., 1993) . Adherent cells were collected in cold PBS by gentle scraping with a rubber policeman. Cells were washed twice in cold PBS and 1 x 106 cells were resuspended in 100 JLl of PBS containing a 1: 1 dilution of human serum with PBS and incubated at 4°C for 30 min to block Fc receptors. Then, 2 ml of PBS was added to the cells, which were collected by centrifugation at 600 g for 3 min. Pelleted cells were resuspended in 100yl of PBS containing 2% goat serum and 10 igmlhl anti-P-gp MAb 4E3 or an IgG2a isotype-matched control antibody. This mixture was incubated for 30 min at 4°C. Cells were then washed twice with cold PBS and then resuspended in 100 jil of PBS containing 2% goat serum and fluorescein isothiocyanate (FITC)-labelled goat anti-mouse Ig (Fab)2 fragment (TAGO) at a 1:30 dilution. Cells were incubated with the second antibody for 30 min at 4°C in the dark, then washed twice in cold PBS and fixed in 2% paraformaldehyde before analysis. The level of P-gp expression was determined using a Becton-Dickinson FACSscan II and LYSYS software application. we repeated and extended the experiments of Beck and Cirtain (1982) using the MDR-competent colon carcinoma cell line clone A. Pulse-chase labelling experiments demonstrated P-gp synthesised as a 140 kDa precursor molecule in clone A, which is converted to the mature 170 kDa glycoprotein over a 4-6 h period (Figure 1 ), consistent with results reported by other groups (Richert et al., 1988) . Figure 2 shows immunoprecipitation of P-gp from clone A cells exposed to tunicamycin (2.5 Lg ml-') demonstrating synthesis of precursor throughout continued exposure to the glycosylation inhibitor. Resolution of the 140 kDa precursor and 170 kDa mature P-gp was observed in the absence of tunicamycin (Figure 2 , lane 1) and when label and drug were added together ( Figure 2, lane 2) . However, 6 h exposure to tunicamycin was sufficient to block completely glycosylation of newly synthesised P-gp (Figure 2 , lane 3) resulting in an unglycosylated precursor molecule which migrates more rapidly than the previously characterised 140 kDa precursor (Figure 2 , compare lower band in lanes 2 and 3). The migrational difference observed in repeated experiments is suggestive of some co-translation glycosylation events associated with the P-gp precursor product.
Functional assessment of tunicamycin on the MDR phenotype If glycosylation of P-gp is required for establishing the MDR phenotype, continuous maintenance of clone A cells in the presence of tunicamycin should compromise the functionality of the efflux pump. Figure 3 shows results from a study in which the zero time point demonstrates that the P-gp antagonist verapamil was able to increase the accumulation of daunorubicin by a factor of 4 when co-administered with daunorubicin, thus confirming the functional activity of P-gp in these cells. However, daunorubicin accumulation was not affected by co-administering tunicamycin over a range of doses in excess of those that block P-gp glycosylation, demonstrating that tunicamycin is not a MDR inhibitor in this system (Figure 3) . These results contrast with those seen after exposing cells to verapamil or tunicamycin for 24 or 36 h (Figure 3 ) when cells were washed free of drug before conducting the daunorubicin accumulation assay. Under these conditions, verapamil had no effect on daunorubicin accumulation, whereas tunicamycin treatment resulted in a time-dependent increase in daunorubicin accumulation, reflecting a loss in P-gp function. These values were established over three separate experiments and represent a 5-to 7-fold reduction in pump efficacy compared with that recorded in untreated or in chronic verapamil-treated, clone A cells. (Figure 4b ), 36 ( Figure 4c ) and 48 (Figure 4d ) h, revealed a reduction in surface-associated P-gp. Figure 4 shows approximately a 1.6-fold reduction in detectable cell-surface P-gp following 48 h exposure to tunicamycin. tunicamycin-treated cells, we performed surface iodination of live cells followed by immunoprecipitation of P-gp from protein-standardised cell lysates. 
Discussion
In this study we have evaluated the role of glycosylation of P-gp in establishing the cellular MDR phenotype. These studies were prompted by the identification of two P-gp mutants in a panel of human colon carcinoma cell lines which displayed altered processing of P-gp, resulting in contrasting MDR phenotypes (Kramer et al., 1993a) . Both cell lines were established before chemotherapy and have not subsequently been exposed to known chemotherapeutic agents, hence representing constitutive expression of P-gp. The Moser cell line has previously been reported to synthesise a 140 kDa P-gp precursor molecule which displays an aberrant carbohydrate moiety (Kramer et al., 1993a) similar to that reported for P-gp in drug-selected Chinese hamster ovary cell lines (Ling et al., 1983) . As with the hamster cell lines, the Moser line displays a competent MDR phenotype in which the altered mature P-gp is both membrane R Kramer et al 674 associated and phosphorylated, two features considered essential components of a completely functional cellular efflux pump. In contrast, DLD-1 synthesised similar levels of 140 kDa P-gp precursor to MDR-competent colon cell lines, e.g. clone A and Moser, and yet displayed little or no MDR phenotype in drug uptake assays (Kramer et al., 1993a) . Consistent with the idea that the 170 kDa P-gp is the phosphorylated membrane-associated species and is responsible for the MDR phenotype, DLD-1 has been shown to have greatly reduced surface-localised P-gp and minimal functionality in drug uptake assays (Kramer et al., 1993a) . These observations suggest that glycosylation of the precursor P-gp is important in establishing a competent MDR phenotype in these cells.
To address this issue in more detail, we have repeated and extended studies initially performed by Beck and Cirtain (1982) , using the colon carcinoma cell line clone A, which has been shown to constitutively express P-gp and display a competent MDR phenotype (Kramer et al., 1993a ). In contrast to previous studies in which drug-resistant cells exposed to tunicamycin for 48 h maintained a competent MDR phenotype (Chou and Kessel, 1981; Beck and Cirtain, 1982) , we found increased drug retention in clone A cells exposed to tunicamycin suggestive of a role for glycosylation in establishing the P-gp-mediated MDR phenotype. Following exposure of clone A cells to tunicamycin (2.5 #ig ml-') for 36 h, retention of daunorubicin was 5-to 7-fold greater than that recorded in clone A cells exposed to verapamil (4 ig ml-') for the same period or in untreated clone A cells.
Interestingly, FACS analysis of tunicamycin-exposed clone A cells, using MAb 4E3, revealed only a 1.6-fold reduction in cell-surface-associated P-gp following 48 h of tunicamycin exposure, although surface iodination and Western blot analysis suggest more significant reductions in membraneassociated P-gp. With the demonstrated effective inhibition of glycosylation by tunicamycin on newly synthesised P-gp, why is the MDR phenotype not completely abrogated? Given that the viability of cells exposed to tunicamycin drops rapidly after 48 h and that the half-life of P-gp is between 48 and 72 h (Richert et al., 1988) , it is clear that a significant proportion of presynthesised P-gp will remain throughout the time course of experiments in this study. Hence, with this approach one would not expect to abolish the P-gp-mediated MDR phenotype within the time frame of these studies. Given this limitation, one explanation for the discrepancy between our results and those of Beck and Cirtain (1982) could relate to the level of expression of P-gp in the cell lines used. The cell line CEM/VLB100 was selected for resistance to vinblastine and expresses high levels of P-gp. Although we have no directly comparable data with clone A, it is likely that the level of P-gp expression in CEM/VLB100 is greater than recorded in clone A, as is the case with other drugselected cell lines (Arceci et al., 1993) . In such circumstances the elevated levels of P-gp together with the extended half-life of the protein combine to maintain sufficient P-gp in the presence of tunicamycin to cope with drug efflux at the concentrations used in drug uptake assays. Hence, only cell lines expressing lower levels of P-gp would exhibit a compromised MDR phenotype in the prsence of tunicamycin. However, should tunicamycin exposure result in premature degradation of newly synthesised P-gp, then reduced overall levels of P-gp could account for the loss of MDR phenotype.
Previous studies involving the characterisation of P-gp glycosylation mutants demonstrated that altered glycosylation of P-gp can occur without compromising the MDR phenotype (Ling et al., 1983) . We have found this to be true in the Moser cell line, in which the altered carbohydrate moiety of the mature P-gp does not prevent membrane localisation and phosphorylation of P-gp resulting in a full MDR phenotype. Whether the unglycosylated 140 kDa P-gp precursor can maintain the MDR phenotype in vivo is unclear, although it has been shown that a functional pump can be established in yeast in the absence of glycosylation (Kuchler and Thorner, 1992) . Iodination studies of clone A cells exposed to tunicamycin suggest that some unglycosylated P-gp is localised at the cell surface under these conditions. Since phosphorylation is considered to be an integral component in the functionality of P-gp, it is interesting to note that phosphorylation of a 140 kDa protein is also detected in tunicamycin-exposed clone A cells. We have never observed this in any case of constitutive expression of P-gp in an extended series of cell lines studied (Kramer et al., 1993a) . Although it is evident that tunicamycin, resulting in the inhibition of glycosylation, can affect the efficacy of the P-gp-mediated efflux pump, it is likely that this is as a consequence of a combination of factors. These include loss of cell-surface-associated P-gp and reduced phosphorylation of persisting P-gp in cells. Although unglycosylated P-gp may prove functional in extracellular assays, the perturbation of translocation to the membrane will compromise its efficacy as a cellular detoxification pathway. These results are consistent with a recent report involving mutation of the conserved N-glycosylation sites of the human P-gp, the findings of which suggest that glycosylation contributes to proper routing or stability of P-gp (Schinkel et al., 1993b) . In this way glycosylation does not contribute to functional aspects of the P-gp pump per se but is required in establishing competent cellular MDR phenotypes.
